ATE219044T1 - Fluorosubstituierte adamantan-derivate - Google Patents
Fluorosubstituierte adamantan-derivateInfo
- Publication number
- ATE219044T1 ATE219044T1 AT98302196T AT98302196T ATE219044T1 AT E219044 T1 ATE219044 T1 AT E219044T1 AT 98302196 T AT98302196 T AT 98302196T AT 98302196 T AT98302196 T AT 98302196T AT E219044 T1 ATE219044 T1 AT E219044T1
- Authority
- AT
- Austria
- Prior art keywords
- relates
- adamantane
- formula
- fluorosubstituted
- containing pharmaceutical
- Prior art date
Links
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical class C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 229940052761 dopaminergic adamantane derivative Drugs 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- -1 fluoro-substituted adamantane Chemical class 0.000 abstract 1
- 230000006984 memory degeneration Effects 0.000 abstract 1
- 208000023060 memory loss Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
- C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/15—Saturated compounds containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Psychology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4465897P | 1997-04-10 | 1997-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE219044T1 true ATE219044T1 (de) | 2002-06-15 |
Family
ID=21933590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98302196T ATE219044T1 (de) | 1997-04-10 | 1998-03-24 | Fluorosubstituierte adamantan-derivate |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6057364A (de) |
| EP (1) | EP0870757B1 (de) |
| JP (2) | JP2951313B2 (de) |
| AT (1) | ATE219044T1 (de) |
| BR (1) | BR9801157A (de) |
| CA (1) | CA2234319C (de) |
| DE (1) | DE69805909T2 (de) |
| DK (1) | DK0870757T3 (de) |
| ES (1) | ES2175614T3 (de) |
| PT (1) | PT870757E (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2147573C1 (ru) * | 1998-08-24 | 2000-04-20 | Волгоградский государственный технический университет | Способ получения адамант-1-иламина и его производных |
| US6444702B1 (en) * | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
| JP2002040648A (ja) * | 2000-07-28 | 2002-02-06 | Sony Corp | 露光方法 |
| US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| US7795468B2 (en) * | 2001-01-19 | 2010-09-14 | Chevron U.S.A. Inc. | Functionalized higher diamondoids |
| JPWO2005123653A1 (ja) * | 2004-06-16 | 2008-04-10 | 旭硝子株式会社 | フルオロアダマンタン誘導体 |
| JPWO2005123650A1 (ja) * | 2004-06-16 | 2008-04-10 | 旭硝子株式会社 | 新規なフッ素化されたアダマンタン誘導体 |
| US7619007B2 (en) * | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| EP2243475B1 (de) | 2005-04-06 | 2016-01-13 | Adamas Pharmaceuticals, Inc. | Kombination von Memantin und Donepezil zur Behandlung von Erkrankungen des ZNS |
| NZ565536A (en) * | 2005-08-31 | 2011-03-31 | Hoffmann La Roche | Pyrazolone derivatives as 11-beta HSD1 inhibitors |
| JP5132238B2 (ja) * | 2007-10-05 | 2013-01-30 | 国立大学法人北海道大学 | フッ素化アダマンタン化合物の製造方法 |
| TWI432188B (zh) * | 2008-12-19 | 2014-04-01 | Merz Pharma Gmbh & Co Kgaa | 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類 |
| JP5385402B2 (ja) | 2008-12-19 | 2014-01-08 | メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン | 肥満細胞媒介疾患を治療するための１−アミノ−アルキルシクロヘキサン誘導体 |
| CA2782556C (en) | 2009-12-02 | 2018-03-27 | Adamas Pharma, Llc | Amantadine compositions and methods of use |
| US20140227184A1 (en) * | 2011-08-19 | 2014-08-14 | The Trustees Of Princeton University | C-halogen bond formation |
| GB201206984D0 (en) * | 2012-04-20 | 2012-06-06 | Univ Manchester | New therapeutic use |
| WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
| RU2616255C1 (ru) * | 2016-05-16 | 2017-04-13 | Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) | ПРИМЕНЕНИЕ (1S,3aR,4R,7aS)-N-(2,2,4,7a-ТЕТРАМЕТИЛОКТАГИДРО-1,4-ЭТАНОИНДЕН-3а-ИЛ)-АЦЕТАМИДА В КАЧЕСТВЕ ИНГИБИТОРА РЕПРОДУКЦИИ ВИРУСА ГРИППА |
| US11548893B2 (en) | 2017-07-15 | 2023-01-10 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection |
| US20210323910A1 (en) * | 2018-08-24 | 2021-10-21 | The University Of Sydney | Adamantanyl-substituted benzamide compounds and their use as p2x7 receptor antagonists |
| EP3721857A1 (de) * | 2019-04-11 | 2020-10-14 | Dentsply DeTrey GmbH | Dentale zusammensetzung |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2937211A (en) * | 1958-10-17 | 1960-05-17 | Du Pont | Chemical process |
| US3352912A (en) * | 1963-07-24 | 1967-11-14 | Du Pont | Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes |
| US3391142A (en) * | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
| US4030994A (en) * | 1971-06-18 | 1977-06-21 | Merck & Co., Inc. | Substitutive fluorination of organic compounds |
| GB1513135A (en) * | 1974-06-04 | 1978-06-07 | Res Inst For Med & Chem Inc | Fluorination process and fluoro steroids |
| FR2514006A1 (fr) * | 1981-10-05 | 1983-04-08 | Nativelle Sa Ets | Acylamino-4 aza-1 adamantanes, procede pour leur preparation, et application en therapeutique |
| ES506669A0 (es) * | 1981-10-29 | 1982-08-16 | Especialidades Farmaco Terape | Procedimiento para la obtencion de un nuevo compuesto deri- vado del acido p-clorofenoxiacetico |
| US4829086A (en) * | 1984-03-14 | 1989-05-09 | Bodor Nicholas S | Soft β-adrenergic blocking agents |
| FR2572399B1 (fr) * | 1984-10-31 | 1987-01-16 | Panmedica Sa | Nouveaux derives de l'adamantanamine, leurs procedes de preparation et medicaments les contenant |
| LU85849A1 (fr) * | 1985-04-11 | 1986-11-05 | Cird | Derives benzonaphtaleniques,leur procede de preparation et leur application dans les domaines pharmaceutiques et cosmetiques |
| US5482940A (en) * | 1988-05-24 | 1996-01-09 | American Home Products Corporation | Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders |
| JP3136206B2 (ja) * | 1991-10-22 | 2001-02-19 | 中外製薬株式会社 | ベンゾジオキサン誘導体 |
| DE69533284T2 (de) * | 1994-04-29 | 2005-07-21 | Pfizer Inc. | Neue cyclische und acyclische amide zur erhöhung der neurotransmitter ausschüttung |
| US5599998A (en) * | 1994-10-24 | 1997-02-04 | Iowa State University Research Foundation, Inc. | Method for the synthesis of adamantane amines |
-
1998
- 1998-03-24 EP EP98302196A patent/EP0870757B1/de not_active Expired - Lifetime
- 1998-03-24 AT AT98302196T patent/ATE219044T1/de not_active IP Right Cessation
- 1998-03-24 DE DE69805909T patent/DE69805909T2/de not_active Expired - Fee Related
- 1998-03-24 PT PT98302196T patent/PT870757E/pt unknown
- 1998-03-24 DK DK98302196T patent/DK0870757T3/da active
- 1998-03-24 ES ES98302196T patent/ES2175614T3/es not_active Expired - Lifetime
- 1998-04-08 BR BR9801157A patent/BR9801157A/pt not_active Application Discontinuation
- 1998-04-08 CA CA002234319A patent/CA2234319C/en not_active Expired - Fee Related
- 1998-04-09 US US09/057,694 patent/US6057364A/en not_active Expired - Fee Related
- 1998-04-09 JP JP10097707A patent/JP2951313B2/ja not_active Expired - Fee Related
-
1999
- 1999-04-27 JP JP11990499A patent/JP3338400B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2175614T3 (es) | 2002-11-16 |
| JP2000026367A (ja) | 2000-01-25 |
| US6057364A (en) | 2000-05-02 |
| JP2951313B2 (ja) | 1999-09-20 |
| DK0870757T3 (da) | 2002-07-15 |
| EP0870757B1 (de) | 2002-06-12 |
| EP0870757A3 (de) | 2000-06-07 |
| EP0870757A2 (de) | 1998-10-14 |
| PT870757E (pt) | 2002-09-30 |
| JP3338400B2 (ja) | 2002-10-28 |
| BR9801157A (pt) | 2000-03-21 |
| CA2234319C (en) | 2003-03-25 |
| DE69805909T2 (de) | 2002-09-26 |
| DE69805909D1 (de) | 2002-07-18 |
| CA2234319A1 (en) | 1998-10-10 |
| JPH10298135A (ja) | 1998-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE219044T1 (de) | Fluorosubstituierte adamantan-derivate | |
| DE69604714D1 (de) | Stilbenderivate und diese enthaltende pharmazeutische Zusammensetzungen | |
| EP0738152A4 (de) | Verwendung von 2-hydroxy-5-phenylazobenzoesäure-derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs | |
| CA2216796A1 (en) | Quinazoline derivatives | |
| ES2087916T3 (es) | Derivado de pirimidina biciclico, metodo para producir el mismo, y preparacion farmaceutica que contiene el mismo como ingrediente activo. | |
| PT87542A (pt) | Process for the preparation of a medicament based on indolone derivatives for the treatment of the parkinson disease | |
| ATE193828T1 (de) | Hypoglykämische dihydrochalconderivate | |
| ATE202337T1 (de) | Cyclopropylalkansäurederivate | |
| RU94046141A (ru) | Замещенные производные /арилалкоксибензил/ аминопропанамида, способы их получения, фармацевтическая композиция | |
| DE69612512D1 (de) | Pyrimidin derivate | |
| BR9503572A (pt) | Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença | |
| WO1996005166A1 (en) | Substituted amine derivative and medicinal composition containing the same | |
| WO1999004770A3 (en) | A pharmaceutical composition active in reducing production of mcp-1 protein | |
| EP0667163A4 (de) | Pulver zur nasalen Verabreichung peptidischer oder proteinischer Arzneistoffe | |
| KR950032171A (ko) | 옥소피리디닐퀴녹살린 유도체 | |
| SE9302333D0 (sv) | New compounds | |
| DK0722724T3 (da) | Anvendelse af L-carnitin og dets derivater til nedsættelse af de toksiske virkninger af cyclosporin-A og andre immunosuppre | |
| ES2153842T3 (es) | Derivados de 3-oxo-pirido(1,2-a-)bencimidazol-4-carboxilo y de 4-oxo-azepino(1,2-a)bencimidazol-5-carboxilo utiles en el tratamiento de enfermedades del sistema nervioso central. | |
| EP0546177A4 (de) | Benzopyran derivat, seine darstellung und pharmazeutische zusammensetzung, welche dieses enthält. | |
| DE69030665D1 (de) | (1,2n) und (3,2n)-karbozyklische-2-amino-tetralinderivate | |
| SE9702716D0 (sv) | Substituted phenylazacycloalkanes in the treatment of cognitive disorders | |
| MX9300638A (es) | Derivados del acido aminobenzoico. | |
| EP0813866A3 (de) | Therapeutisches Mittel gegen Gelenkserkrankungen | |
| ATE316788T1 (de) | Medikament gegen pulmonale herzprobleme | |
| EP0702014A4 (de) | Dc-89 derivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |